Sanofi, Mass General collaborate on cancer drug research; GSK teams with Aeras on TB vaccine;

Conversations on Twitter :

 @FierceBiotech: Diamyd Medical sells off nerve-targeted delivery unit. More | Follow @FierceBiotech

 @JohnCFierce: I'd like to see Lilly file an NDA on sola, see how regulators handle secondary analysis on data from 1 trial that couldn't be confirmed in 2nd. | Follow @JohnCFierce

 @RyanMFierce: Top counterfeit drug events in 2012 report, shows this problem affects all of us. More | Follow @RyanMFierce

> Sanofi ($SNY) will collaborate with the Massachusetts General Hospital on a two-year translational medicine pact covering the development of new cancer drugs. Scientists from both will be spearheading efforts to obtain proof-of-concept data on drugs. Sanofi has been steadily building up its R&D presence in Boston. Release

> GlaxoSmithKline ($GSK) says it will team up with the nonprofit Aeras group to test an experimental TB vaccine. Story

> QRxPharma has executed a pact with Paladin Labs for the Canadian commercialization rights to MOXDUO, an immediate release formulation of morphine and oxycodone. Release

Pharma News

@FiercePharma: Will Optimer's plan to boost Dificid sales work? It's a volume-pricing move. More | Follow @FiercePharma

> Teva's 2nd-gen Copaxone makes the grade. Report

> No breakup for J&J? Goldman analyst says 'Sell'. Story

> Pfizer wraps up Celebrex suit in $164M settlement. News

> Should new drugs wear 'proceed with caution' labels? Article

Medical Device News

 @FierceMedDev: Check out our rundown of the year's biggest announced layoffs in the medical device world. More | Follow @FierceMedDev

 @MarkHFierce: BD's CFO is leaving to pursue an "entrepreneurial opportunity." More | Follow @MarkHFierce

 @DamianFierce: Biomet reduced its quarterly losses thanks to its $280M buy of DePuy's trauma unit. More | Follow @DamianFierce

> Hospital transparency may be driving down stent use. Report

> Researchers: Concealing a stent with antibodies will prevent clots. Story

> Study: FDA, CMS device approval times still run long. Item

Drug Delivery News

> NuPathe axes half its workforce, sells $28M of securities. Article

> Dissolving microneedles hit the sweet spot in diabetes. Item

> Diamyd Medical sells off nerve-targeted delivery unit. Story

> Smaller electric pulse hits the spot for DNA vaccines. Report

Biomarkers News

> Scratching a genetic itch in atopic dermatitis. More

> Biomarker panel spots the risk of Type 2 diabetes. Report

> Making a GENIE-us connection: Linking genes with diabetic kidney disease. Story

> Prostate cancer genetic barcodes predict aggressiveness. Article

And Finally… Investigators at the University of Illinois say they think they know why coffee has been linked to a reduction in risk for Alzheimer's, suggesting that the caffeine may be blocking inflammation that causes cognitive problems. Story

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.